Alvogen unit appeals court loss in bid to market Xifaxan generic
Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch Health's Xifaxan to market, the company said. On Friday, its subsidiary Norwich Pharmaceuticals appealed a ...
